-
A polypill consisting of low doses of thiazide, atenolol, ramipril, simvastatin, and aspirin administered to 2053 subjects in 50 centers in India was effective in reducing multiple risk factors and cardiovascular risk.
-
The FDA has approved the first oral, selective vasopressin V2-receptor antagonist for the treatment of hypervolemic and euvolemic hyponatremia.
-
The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
-
Preclinical data recently demonstrated the extreme sensitivity of BRCA-deficient cells to inhibition of the single-strand repair enzyme poly(ADP-ribose) polymerase (PARP).
-
About 30 years ago (so long ago that I can't remember the exact year), I began to edit a monthly newsletter devoted to reproductive medicine.
-
In this issue: Comparing blood pressure medications, determining optimal length of androgen-deprivation therapy, red yeast rice for LDL reduction, and FDA Actions.
-
-
A large prospective randomized trial (n = 2812 women) was retrospectively analyzed to look at contraceptive efficacy and weight/BMI.
-
The raloxifene use for the heart (RUTH) trial was an international randomized, placebo-controlled trial that enrolled 10,101 postmenopausal women in two groups, one at high risk for coronary heart disease, and one with established coronary heart disease.
-
June seems to have been magnesium sulfate month in both the Obstetrics & Gynecology and American Journal of Obstetrics & Gynecology journals.
